378 related articles for article (PubMed ID: 26627075)
61. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
[TBL] [Abstract][Full Text] [Related]
62. Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab.
Dickson L; Menter A
J Drugs Dermatol; 2017 Feb; 16(2):177-179. PubMed ID: 28300862
[TBL] [Abstract][Full Text] [Related]
63. Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre.
Vergou T; Moustou AE; Antoniou C
J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):e40-e41. PubMed ID: 27038363
[No Abstract] [Full Text] [Related]
64. Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus.
Mazgaj M; Picard-Dahan C; Deschamps L; Marinho E; Estève E; Descamps V
Int J Dermatol; 2020 Apr; 59(4):e118-e120. PubMed ID: 31957866
[No Abstract] [Full Text] [Related]
65. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
Croxtall JD
Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
[TBL] [Abstract][Full Text] [Related]
66. Successful treatment of severe psoriasis in an adolescent with ustekinumab.
AbuHilal M; Ho N
Pediatr Dermatol; 2015; 32(3):377-80. PubMed ID: 25727845
[TBL] [Abstract][Full Text] [Related]
67. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
Pescitelli L; Dini V; Gisondi P; Loconsole F; Piaserico S; Piccirillo A; Stinco G; Errichetti E; Talamonti M; Tripo L; Volpi W; Prignano F
J Dermatol Sci; 2015 May; 78(2):149-51. PubMed ID: 25681953
[No Abstract] [Full Text] [Related]
68. Treatment of severe psoriasis with ustekinumab during pregnancy.
Andrulonis R; Ferris LK
J Drugs Dermatol; 2012 Oct; 11(10):1240. PubMed ID: 23134993
[TBL] [Abstract][Full Text] [Related]
69. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.
Čarija A; Ivić I; Marasović-Krstulović D; Puizina-Ivić N
Rheumatology (Oxford); 2015 Nov; 54(11):2114-6. PubMed ID: 26242857
[No Abstract] [Full Text] [Related]
70. Tattoo sites and psoriasis.
Smith SF; Feldman SR
J Drugs Dermatol; 2011 Oct; 10(10):1199-200. PubMed ID: 21968672
[TBL] [Abstract][Full Text] [Related]
71. Long persistence of tumour necrosis factor-α antagonist-induced autoantibodies under subsequent treatment with ustekinumab but no adverse effects: a case study of 14 patients with psoriasis.
Hoffmann JHO; Knoop C; Enk AH; Hadaschik EN
Br J Dermatol; 2018 Jan; 178(1):e9-e10. PubMed ID: 28581119
[No Abstract] [Full Text] [Related]
72. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection.
Saeki H; Ito T; Hayashi M; Fukuchi O; Umezawa Y; Nobeyama Y; Teruya K; Nakagawa H
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1653-5. PubMed ID: 24754476
[No Abstract] [Full Text] [Related]
73. Biologicals in the treatment of psoriasis.
Boker A; Kimball AB; Rolz-Cruz G
Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
[TBL] [Abstract][Full Text] [Related]
74. Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.
Med Lett Drugs Ther; 2017 Jul; 59(1525):118-119. PubMed ID: 28699932
[No Abstract] [Full Text] [Related]
75. Ustekinumab for the treatment of moderate to severe psoriasis.
Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
[TBL] [Abstract][Full Text] [Related]
76. Therapeutics: Silencing psoriasis.
Crow JM
Nature; 2012 Dec; 492(7429):S58-9. PubMed ID: 23254974
[No Abstract] [Full Text] [Related]
77. Ustekinumab for the treatment of psoriasis: an evidence update.
Yiu ZZ; Warren RB
Semin Cutan Med Surg; 2018 Sep; 37(3):143-147. PubMed ID: 30215630
[TBL] [Abstract][Full Text] [Related]
78. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
[No Abstract] [Full Text] [Related]
79. Ustekinumab and herpes zoster.
Failla V; Nikkels AF
Dermatology; 2011; 222(2):119-22. PubMed ID: 21266799
[TBL] [Abstract][Full Text] [Related]
80. Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent.
Bertrand V; El Haite A; Carré D
Pediatr Dermatol; 2017 Jul; 34(4):e214-e215. PubMed ID: 28436109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
